Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A Phase II Randomized Active Comparator-Controlled Clinical Trial to Study the Safety Tolerability and Efficacy of MK-7655 ImipenemCilastatin Versus ImipenemCilastatin Alone in Patients with Complicated Intra-Abdominal Infection cIAI

1 To evaluate the efficacy of two doses of MK-7655 imipenemcilastatin 250 mg and 125 mg as compared with imipenemcilastatin alone with respect to the clinical response assessment profile in the treatment of adult patients with cIAI at completion of IV study therapy DCIV 2 To evaluate the safety and tolerability profile of two doses of MK- 7655 imipenemcilastatin 250 mg and 125 mg

FieldValue
Modified
2020-03-29
Release Date
2018-09-13
Identifier
fc87f2c3-3a65-4eea-88d1-671fabf9cefc
License
Public Access Level
Public